Business

Vicon Industries Unveils Terms of Rights Offering

Vicon Industries Unveils Terms of Rights Offering

Vicon Industries (VII) disclosed late Tuesday the terms of its rights offering, saying it will distribute one non-transferable subscription right for each share of the company’s common stock owned, at no charge, to the holders of its common stock as at Sept. 22. Each subscription right will entitle the holder to purchase one share of common stock at the subscription[Read More…]

by September 21, 2017 0 comments Business
Argenx Reaches 50% Enrollment in Phase 2 Study of ARGX-113 For Autoimmune Diseases

Argenx Reaches 50% Enrollment in Phase 2 Study of ARGX-113 For Autoimmune Diseases

Argenx SE (ARGX) said Wednesday that it has recruited 50% of the immune thrombocytopenia (ITP) patients in the phase 2 proof-of-concept study of ARGX-113, an investigational therapy for treatment of IgG-mediated autoimmune diseases. The study will enroll up to 36 ITP patients with platelet levels lower than 30 million per milliliter. ARGX-113 will be dosed on top of current standard[Read More…]

by September 21, 2017 0 comments Business
Eagle Pharma Licenses Rights to Injection Products For Blood Cancers to Japan’s Symbio Pharma

Eagle Pharma Licenses Rights to Injection Products For Blood Cancers to Japan’s Symbio Pharma

Eagle Pharmaceuticals (EGRX) said Wednesday it has licensed rights to develop, market and sell injection products for blood cancers to Tokyo-based SymBio Pharmaceuticals. The company said SymBio will be responsible for obtaining regulatory approval of Eagle’s bendamustine hydrochloride (bendamustine HCI) ready-to-dilute and rapid infusion injection products in Japan, with a target for product approval in 2020. Under the terms, Eagle[Read More…]

by September 21, 2017 0 comments Business
Red Hat PT Boosted by RBC to $121 From $106 Ahead of Q2 Results

Red Hat PT Boosted by RBC to $121 From $106 Ahead of Q2 Results

Red Hat (RHT) received a price-target increase Wednesday from RBC Capital Markets ahead of the open-source-software company’s fiscal Q2 report expected Sept. 25. The new price target is $121 per share, up from $106. The boost brings the target above the stock’s Tuesday closing price of $107.14 from below it. RBC said the price-target increase comes amid expectations for estimates[Read More…]

by September 21, 2017 0 comments Business
Gold, Treasuries, Yen, Swiss Getting a Bid in Early Trading

Gold, Treasuries, Yen, Swiss Getting a Bid in Early Trading

Dealers are reporting some early action with gold, Treasuries, yen and Swiss all bid. Retail starts on the back foot with Bed Bath & Beyond (BBBY) stock off 13% while FedEx (FDX) numbers take a toll on shares. In Europe it’s mixed with the Dax off small and Fins under pressure as the EU expands supervision of banks and insurers.[Read More…]

by September 21, 2017 0 comments Business